
    
      Study design:

      â€¢ Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.

      Study design:

        -  Experiment duration: 30 weeks

        -  9 visits (days 0, 14, 42, 70, 98, 126, 154, 182, 210)

        -  Health Assessment Questionnaire (HAQ) evaluation

        -  Disease Activity Score (DAS28) evaluation

        -  Clinical Disease Activity Index (CDAI) evaluation

        -  American College of Rheumatology criteria (ACR) evaluation

        -  Visual Activity Schedule(VAS) evaluation

        -  Adverse events evaluation
    
  